SubHero Banner

Sarclisa® (isatuximab-irfc) – New orphan drug approval

March 2, 2020 - The FDA announced the approval of Sanofi’s Sarclisa (isatuximab-irfc), in combination with Pomalyst® (pomalidomide) and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid® (lenalidomide) and a proteasome inhibitor.

Download PDF